Episode Details
Back to Episodes
Episode 505 : ASCO 2026 - RAMPART
Published 4 months, 3 weeks ago
Description
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.